Reuters logo
BRIEF-Arbutus licenses LNP delivery technology to Alexion
2017年3月16日 / 晚上10点28分 / 8 个月前

BRIEF-Arbutus licenses LNP delivery technology to Alexion

March 16 (Reuters) - Arbutus Biopharma Corp

* Arbutus licenses LNP delivery technology to Alexion for use in single messenger RNA product candidate

* Arbutus Biopharma Corp says under terms of license agreement, Alexion will pay Arbutus $7.5 million upfront

* Arbutus Biopharma Corp says Alexion will also make payments of up to $75 million for achievement of development, regulatory, and commercial milestones

* Arbutus Biopharma Corp says transaction enables Alexion to address delivery for therapeutic application of messenger RNA

* Arbutus Biopharma Corp says transaction also enables Alexion to rapidly enter clinical development with its MRNA product candidate

* Arbutus Biopharma - licensed to Alexion Pharma its proprietary lipid nanoparticle technology for exclusive use in one of Alexion’s rare disease programs Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below